Clinical Trial Update: Safety Study of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease [Phase 2]

View source ↗

Summary

Phase 2 safety study of Tecemotide (L-BLP25) in patients with unresectable Stage III non-small cell lung cancer has completed, with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tecemotide (L-BLP25) (tecemotide)

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2015-08-18